News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|December 22, 2022

Impact of MDD Episode Duration and Recurrences

Author(s)Gustavo Alva, MD, DFAPA, Charles Montano, MD, Carmen Kosicek, MSN, PMHNP-BC

Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.

Episodes in this series

EP. 1 Impact of MDD Episode Duration and Recurrences

EP. 1 Impact of MDD Episode Duration and Recurrences

EP. 2 Depression and Comorbid Health Conditions

EP. 2 Depression and Comorbid Health Conditions

EP. 3 Perception of MDD in the Healthcare Community

EP. 3 Perception of MDD in the Healthcare Community

EP. 4 Monitoring Recommendations for MDD

EP. 4 Monitoring Recommendations for MDD

EP. 5 Treatment Options for MDD

EP. 5 Treatment Options for MDD

EP. 6 Treatment Approaches for Episodic and Chronic MDD

EP. 6 Treatment Approaches for Episodic and Chronic MDD

EP. 7 Current Challenges With MDD Treatment Options

EP. 7 Current Challenges With MDD Treatment Options

EP. 8 Impact of Different MDD Classes of Treatment on Time to Response

EP. 8 Impact of Different MDD Classes of Treatment on Time to Response

EP. 9 Unmet Needs in MDD Treatment Paradigm

EP. 9 Unmet Needs in MDD Treatment Paradigm

EP. 10 Key Takeaways for the Management of MDD

EP. 10 Key Takeaways for the Management of MDD

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD